BACKGROUND: Microvascular decompression (MVD) is the reference technique for pharmacoresistant trigeminal neuralgia (TN). OBJECTIVE: To establish whether the safety and efficacy of Gamma Knife surgery for recurrent TN are influenced by prior MVD. METHODS: Between July 1992 and November 2010, 54 of 737 patients (45 of 497 with .1 year of follow-up) had a history of MVD (approximately half also with previous ablative procedure) and were operated on with Gamma Knife surgery for TN in the Timone University Hospital. A single 4-mm isocenter was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm (range, 3.9-11.9 mm) anterior to the emergence of the nerve. A median maximum dose of 85 Gy (range, 70-90 Gy) was delivered. RESULTS: The median follow-up time was 39.5 months (range, 14.1-144.6 months). Thirty-five patients (77.8%) were initially pain free in a median time of 14 days (range, 0-180 days), much lower compared with our global population of classic TN (P = .01). Their actuarial probabilities of remaining pain-free without medication at 3, 5, 7, and 10 years were 66.5%, 59.1%, 59.1%, and 44.3%. The hypoesthesia actuarial rate at 1 year was 9.1% and remained stable until 12 years (median, 8 months). CONCLUSION: Patients with previous MVD showed a significantly lower probability of initial pain cessation compared with our global population with classic TN (P = .01). The toxicity was low (only 9.1% hypoesthesia); furthermore, no patient reported bothersome hypoesthesia. However, the probability of maintaining pain relief without medication was 44.3% at 10 years, similar to our global series of classic TN (P = .85).
T rigeminal neuralgia (TN) is a very disabling facial pain disorder. Several surgical methods, including balloon microcompression, percutaneous radiofrequency, percutaneous glycerol rhizotomy, microvascular decompression (MVD), and Gamma Knife surgery (GKS), are the possible options to discuss when pharmacological treatment fails.
Several articles address the issue of the safety and efficacy of MVD after $1 GKS treatments. 1, 2 To the best of our knowledge, there are no studies discussing the role of GKS as a retreatment for recurrent TN after a previous MVD.
GKS for TN was introduced by the Swedish neurosurgeon Lars Leksell 3 and further refined by several others. [4] [5] [6] [7] [8] [9] [10] [11] [12] GKS is currently considered the least invasive treatment with the lowest rate of adverse effects and a similar rate of initial efficacy. 11, 13 MVD of the trigeminal nerve at the root entry zone was initially carried out on the basis of the observations made by Dandy 14 with a technique developed by Gardner and Miklos and further perfected by Janetta. 15 Although frequently accepted as a first-line option, its failure rates vary between 15% and 35%, as reported in studies with long-term follow-up. 16, 17 Additionally, MVD is sometimes attempted in the absence of a clear vascular compression and consequently without necessarily an objective compression of the trigeminal root. 18 The purpose of the present study was to establish on a long-term follow-up whether the results in terms of safety and efficacy in patients treated with GKS for recurrent, classic TN (CTN) could be affected by prior MVD treatment. The population of recurrent TN patients with prior MVD was deemed especially relevant because MVD is regarded as the reference technique. Moreover, although the outcomes of MVD after previous GKS are well established, 1, 2, 5, [19] [20] [21] [22] [23] [24] outcomes of GKS after previous MVD have not been reported so far.
METHODS

Type of Study
The study was designed as open, self-controlled, noncomparative, and prospective. For all patients, a case report form was created and prospectively completed. All patients were examined before treatment, and a magnetic resonance imaging (MRI) was done (the latest to exclude any secondary cases). Ethics committee (CPPRB1) permission was obtained for this study.
Diagnostic Criteria Using the International Headache Society Definition
All patients fulfilled the criteria of the International Headache Society. 25 The type of trigeminal pain was evaluated according to the classification proposed by Eller et al, 26 comprising idiopathic TN1 and TN2. TN1 is described as typically sharp, shooting, and electric shocklike pain with pain-free intervals between the attacks that is present .50% of the time; TN2 is described as an aching, throbbing, or burning pain that is present for .50% of the time and is constant in nature (constant background pain being the most significant attribute). Only patients fulfilling the criteria of the TN1 type were included.
Fifty-four patients (7.3%) from our global series of 737 patients had undergone a previous MVD. We further analyzed 45 patients with .1 year of follow-up. All patients with a history of multiple sclerosis 27 or megadolichobasilar artery compression 28 were excluded from the present analysis (reputed to have more variable results). The mean time of GKS after MVD was 67.7 months (range, 6-326 months).
Brief Description of GKS Technique
All patients underwent GKS. After application of the Leksell Model G stereotactic frame (Elekta Instruments AB, Stockholm, Sweden) under local anesthesia, all patients underwent stereotactic MRI (unless there were formal contraindications) and computed tomography for target definition. The MRI sequences used to identify the trigeminal nerve were T2-type constructive interference in steady state/fast imaging employing steady-state acquisition (Siemens; 0.5-mm thickness) without contrast and contrast-enhanced T1-weighted images. Bone computed tomography routinely supplements the neuroimaging investigation to correct any distortion errors on the MRIs. 10, 12 Between July 1992 and November 2010, models B, C, and 4C of the Gamma Knife (Elekta Instruments AB) were used successively.
A single 4-mm isocenter was used for all 45 patients (100%) and was positioned in the cisternal portion of the trigeminal nerve at a median distance of 7.6 mm (range, 3.9-11.9 mm) anterior to the emergence of the nerve. This target had been used in our center since the beginning of GKS treatments for TN, as detailed in previous studies. 10, 11, 29 The placement of the target depended on the individual anatomy of the patient and on the local neurovascular conditions. Because these patients already had a previous MVD procedure, sometimes the trigeminal nerve turned out to be more difficult to identify (eg, the presence of the Teflon felt and postoperative changes; Figure 1 ).
A median maximum dose of 85 Gy (range, 70-90 Gy) was delivered. The dose had been chosen according to the multicentric trial of Kondziolka et al 30 (which also included an important number of patients from our center), which recommended a minimal dose of 70 Gy for short-and longterm efficacy. According to the aforementioned findings, we initially prescribe a dose of 90 Gy at the 100% isodose. Beam channel blocking was used, depending on the dose received by 10 mm 3 of the brainstem. If this dose was found to exceed 15 Gy, we scaled down the dose and then started plugging to avoid irradiating a longer length of the treated nerve, which has been previously shown to dramatically increase toxicity (the so-called Flickinger effect). 7 All patients were operated on with GKS by the senior neurosurgeon (J.R.).
Follow-up Monitoring
Initial follow-up was based on clinical evaluation at regular intervals of 3 months, 6 months, and 1 year after treatment and on a yearly basis thereafter. All patients have been thoroughly examined by the authors for proper evaluation of safety and efficacy, including facial sensory testing, corneal reflex, and jaw motility. For long-term update of the follow-up, telephone interview was considered acceptable for patients unable to come to the outpatient clinic because of either distance or general health-related conditions.
The patients and referring physician were instructed to pursue the preoperative medication for at least 1 month after GKS and then were allowed to progressively taper the drug doses in cases of pain freedom.
Every clinical evaluation made by our medical team during the course of follow-up was reported prospectively in the database to have continuous and prospective up-to-date information.
The 15 items of essential data as given by Zakrzewska and Thomas 31 for the articles reporting outcomes of surgical treatment of TN were followed and are presented hereafter.
Explicit Definitions of Outcome Measures
Outcome measures included the existence of initial pain cessation, occurrence and timing of any sensory disturbance, recurrence, and recurrence without further surgery.
Efficacy was classified according to the Barrow Neurological Institute (BNI) scale (class I, no trigeminal pain, no medication; class II, occasional pain not requiring medication; class IIIa, no pain, continued medication; class IIIb, persistent pain controlled with medication; class IV, some pain not adequately controlled with medication; class V, severe pain/no pain relief; grade I-IIIa, significant pain relief; grade I-IIIb, adequate pain relief; and grade IV and V are failures). 10 A successfully treated patient needed to be pain free without medication (BNI class 1).
The degree of hypoesthesia was reported with the use of the BNI facial hypoesthesia scale 32 (class I, no facial numbness; class II, mild facial numbness, not bothersome; class III, facial numbness, somewhat bothersome; class IV, facial numbness, very bothersome). Corneal reflex was assessed for all patients. Additionally, the appearance or not of dysesthesias, paresthesias, anesthesia dolorosa, masseter muscle weakness, neurological complications outside the trigeminal nerve territory, systemic complications, or death was noted.
Recurrence was defined as change from class I to a lower outcome class during the follow-up.
The latency intervals to becoming pain free or developing a recurrence or a sensory disturbance, the date of medication changes, and the date of all surgical procedures were also carefully monitored.
Definition of Recurrence (Minor and Major)
A minor recurrence was defined as well tolerated by the patient (lower frequency and intensity of the pain) and not requiring a new surgical therapy.
A major recurrence was defined as requiring an additional surgical procedure. We use the term initial efficacy when the patient was pain free with or without medication in the first 6 months after the radiosurgery and had no recurrence in the year after the procedure.
Patient Satisfaction
Patient satisfaction was evaluated during the last follow-up. We used a semistructured interview conducted by the GKS team during the followup visits. Patients were asked if they regret undergoing radiosurgery and if they would agree to undergo this procedure again. The answers in our semistructured questionnaire included the following: a, no regret, I would undergo radiosurgery again with no hesitation; b, no opinion; and c, I regret having had radiosurgery (and would not have it again).
Details of Follow-up Period (Including Median and Range)
The median follow-up period was 39.5 months (range, 14.1-144.6 months).
Basic Demographic Data
The median age was 56.7 years (range, 28.1-82.4 years). Pain was slightly predominant on the left side in 26 patients (57.8%) vs on the right side in 19 (42.2%). Only 2 patients (4.4%) had bilateral pain. Pain was mainly distributed in the V2 dermatoma in 17 patients (37.8%), followed by V2 and V3 territory in 12 patients (26.3%); V1, V2, and V3 in 3 patients (6.7%); and V1and V2 in 2 patients (4.4%; Table 1 ). 
Data of Side Effects Related to Prior Surgical Interventions
Twenty-three patients (51.1%) had preoperative hypoesthesia, which was mild in 21 patients (46.7%) and severe in 2 patients (4.4%). In no patient was preoperative anesthesia present.
Statistical Analysis
All statistical analyses were performed with R software, version 2.12.0 (R Foundation for Statistical Computing, Vienna, Austria). The survival R package was used for survival analysis. For the evaluation of outcomes such as pain free, hypoesthesia, and recurrence, the time to event was estimated by use of the Kaplan-Meier method. A bivariate analysis was then performed to identify predictive factors among the collected variables. For qualitative variables, Kaplan-Meier curves were used to graphically represent survival among the different groups and were compared by use of the univariate log-rank test. For all variables, the effects were estimated and tested by fitting univariate Cox proportional hazards regression models. Proportionality of hazards was assessed graphically by log cumulative hazard plots. For qualitative variables, the x 2 test was performed when valid; the Fischer exact test was performed otherwise. For quantitative variables, the Mann-Whitney test was performed given the number of patients. All tests were 2 sided, and values of P ,.05 were judged to be significant.
RESULTS
Initial Pain Cessation
Thirty-five patients (77.8%) experienced initial pain cessation in a median time of 14 days (range, 0-180 days). The initially painfree (BNI classes I-IIIa) actuarial rate at 14 days and 1, 2, 3, 4, 5, and 6 months was 46.7%, 62.2%, 71.1%, 73.3%, 73.3%, 73.3%, and 77.8%, respectively, attaining at 6 months the flat part of the curve and remaining stable thereafter. Of note, the number of patients at risk at 0.5, 1, 2, 3, 4, 5, and 6 months was 24, 17, 13, 12, 12, 12, and 10, respectively, and the number of events was 21, 7, 4, 1, 0, 0, and 2, respectively.
Patients with previous MVD had a significantly lower probability of initial pain cessation compared with our global population of patients with CTN with no history of MVD (P = .01; hazard ratio [HR], 0.64). Figure 2 shows the probability of being pain free in patients with a previous MVD procedure compared with those from our series of 497 patients with CTN. Bilateral pain (P = .65), continuous pain (P = .19), atypical pain (P = .61), and the number of previous surgeries (P = .07 for 1 previous surgery, Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited P = .12 for 2 previous surgeries, P = .18 for $3 surgeries) were not shown to be statistical factors.
Patients with both previous MVD and thermocoagulation had a lower probability of pain cessation, but this was not statistically significant (HR, 0.53; 95% confidence interval [CI], 0.25-1.11; P = .08).
Age (P = .11), topography of pain (P = .46), and time lapse to treatment onset (P = .65) also showed no statistically significant correlation.
Postoperative Sensory Assessment and Details of Other Postoperative Complications if the Case
No patient developed an early complication after GKS. Two patients (4.4%) developed delayed facial sensory loss, which occurred in both patients within the first year after the GKS. Hypoesthesia actuarial rate at 1 year was 9.1% and remained stable until 12 years with a median delay of onset of 8 months. Figure 3 shows the probability of hypoesthesia onset after GKS in patients with previous MVD.
Postoperative hypoesthesia was also assessed regarding the BNI facial hypoesthesia scale: mild facial numbness was found in 2 patients (4.4%); facial numbness, somewhat bothersome, 0 patients (0%); and facial numbness, very bothersome in 0 patients (0%). Table 3 shows the postoperative assessment in terms of hypoesthesia, recurrence, and management of recurrence.
The side of the pain in patients with post-GKS hypoesthesia was not a statistically significant correlation (P = 1).
Bilateral pain (P = .04) and previous side effects (P = .04) were associated with a higher incidence of sensory disturbance.
The topography of the pain (P = .7), the number of previous surgeries (P = .3), the persistence of a preoperative neurovascular conflict (P = .2), and sex (P = 1) showed no statistically significant correlations.
No patient developed a trigeminal motor deficit or other cranial nerve deficits after GKS.
Management and Results of Recurrent Pain
Twelve patients (34.3%) from the initially pain-free 35 patients experienced a recurrence in a median time of 31.2 months (range, 3.4-89.9 months).
Additional surgical treatment was performed for 7 patients, with 1 further surgery in 5 patients (11.1%) and 2 additional procedures in 2 cases (4.4%); $3 surgeries were never performed (0%). In our department, the most frequently used was balloon microcompression in 3 patients (6.7%), followed by radiofrequency lesion in 3 patients (6.7%), second MVD in 1 patient (2.2%), second GKS in 1 patient (2.2%), and cortical stimulation and glycerol rhizotomy in 0 patients.
The actuarial probability rates of maintaining pain relief without medication were 88.6%, 66.5%, 59.1%, and 44.3% at 1, 3, 5, and 10 years, respectively; the flat part of the curve was reached at 10 years (Figure 4 ). Patients with previous MVD had a probability of maintaining pain relief similar to that of our global population of CTN without a previous MVD (P = .85; HR, 1.06). 33 Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited A preoperative pain distributed in the V1 dermatome was related to a much higher probability of recurrence (P = .03; HR, 7.16; 95% CI, 1.19-42.96).
Having $3 previous surgical interventions was associated with a higher probability of maintaining pain relief, but this was not statistically significant (P = .10).
The persistence of a neurovascular conflict despite the previous MVD at the moment of GKS was associated with a higher probability of recurrence (P = .03; HR, 3.97; 95% CI, 1.06-14.89).
The existence of postoperative GKS hypoesthesia onset was not statistically significant (P = .15).
The Probability of Recurrence Not Requiring Further Surgery
Among the 12 patients (34.3%) who experienced a post-GKS recurrence, 7 needed a further surgery. The actuarial probability of recurrence not requiring any further surgery at 1, 3, and 5 years was 94.3%, 80.3%, and 73%, respectively, and remained stable until 12 years. Sex (P = .5), age (P = .6), post-GKS hypoesthesia onset (P = .9), side of preoperative pain (P = .19), bilateral pain (P = .6), atypical pain (P = .9), and continuous pain (P = .7) were not found to be statistically significant factors.
The presence of preoperative pain within the V1 dermatome was associated with a higher risk of recurrence with further surgery (P = .01; HR, 23.47; 95% CI, 2.11-260.52).
The number of territories involved in the preoperative pain was not statistically significant (P = .06, with the highest rate of recurrence with further surgery in 3 dermatomes involved; HR, 23.47; 95% CI, 2.11-260.52).
Previous MVD Cases vs Previous MVD Plus Another Procedure
Slightly fewer than half of our patients (approximately 45%) had also undergone another intervention. We looked for potential selection bias in this population. We compared mainly the outcomes for previous MVD as unique intervention and previous MVD plus another surgical procedure. The results were not statistically significant and were as follows: for initial pain freedom response, P = .65 (HR, 0.858; 95% CI, 0.43-1.67); for hypoesthesia, P = .27 (HR, 4.74; 95% CI, 0.29-75.9); and for maintaining pain relief, P = .28 (HR = 0.508; 95% CI, 0.14-1.73).
Furthermore, for the group with only previous MVD, 7 patients had preoperative hypoesthesia and 18 (28%) did not. For the group with previous MVD plus another surgical procedure, 16 patients had a preoperative hypoesthesia and 4 did not (80%). This difference is statistically significant (P , .001). However, this point is not relevant because the patients harboring a hypoesthesia before GKS were not analyzed in terms of facial sensory disturbance.
DISCUSSION
To date, several studies have addressed the alleged technical difficulties when MVD is performed after previous GKS. 1, 2, 5, 22, 24, 34, 35 To the best of our knowledge, there is currently no study describing GKS after MVD or the doseplanning difficulties regarding the GKS trigeminal nerve targeting after previous MVD. However, clinicians must cope with this particular situation.
It is known that pain relief tends to occur immediately after MVD and is delayed after GKS. This fact has to be balanced with the postoperative recovery after both MVD (eg, a few weeks) and GKS (eg, usually the next day) techniques. Previous studies have shown a positive association with pain freedom for both MVD and GKS, including the following: absence of multiple sclerosis, 4, 12, 21 absence of a prior surgical procedure, [36] [37] [38] absence of atypical features, 10, 11, 36, 38 and blood vessel in contact with the trigeminal nerve on preoperative MRI. 39 The rate of pain relief in our present study was 78%, less than reported for CTN general series (including ours) 4, 6, [8] [9] [10] 12 and less than in the opposite scenario (MVD after prior GKS), as reported by others. 1 Hypoesthesia occurrence is similar in both surgical therapies, with GKS carrying a lower risk of the major complications of surgery, including infection, meningitis, cerebellar edema or hemorrhage, cerebrospinal fluid leak, and hearing loss. 13, 40 Recurrence rates in the long term are similar, with the risk of recurrence continuing as long as patients are followed up. 6, 8, 12, 13, 16, 17, 41 Visualizing the nerve after a prior MVD remains the most problematic issue for GKS. Postoperative displacement of the Teflon, the size of the trigeminal nerve (atrophy or not) and trigeminal cistern, the persistence or not of a neurovascular conflict, and other similar anatomic constraints make the targeting much more challenging than in the classic situations. In these cases, the postoperative result depends on proper targeting; this is a crucial issue for the clinical outcomes both in terms of safety and efficacy.
Limitations
The results presented should be interpreted carefully and may not be generalizable to all patients treated with GKS after previous MVD for recurrent TN. The personalized analysis of the patients, including duration of symptoms, number and type(s) of previous surgical procedure(s), time lapse since the previous surgery (or in particular between prior MVD and GKS), and typical or atypical pain, should also be carefully evaluated. Therefore, our study has several limitations: the different surgical techniques used during previous MVD, the image qualities when GKS was performed (with visualization of the treated nerve frequently being difficult and varying from one patient to another according to previous surgery), local anatomy (small vs large trigeminal cistern, presence of Teflon, etc), and targeting location as a factor affecting the initial efficacy of GKS, depending on individual anatomy. Additionally, other potential limitations reside in the lack of a control arm or the eventual use of a propensity score-matched control group. Some subgroup analysis in the Discussion might also have been underpowered because of the small number of patients and events taken into consideration. The data set might, in this context, not exclude the possibility that patients with 2 procedures (including, for instance, MVD and 1 ablative) could have a worse prognosis than those with prior MVD only.
The message of this study should not be misinterpreted. We are not advocating that GKS should not be performed on patients with previous MVD procedures because of an initial pain relief rate that is lower than in CTN cases. On the contrary, it may be that these patients harbored a particular type of disease that also was resistant to the first MVD procedure. Therefore, in these situations, we must be aware of the fact that these patients may be more difficult to manage surgically. Conversely, studies also showed a decrease in the initial efficacy of MVD after previous destructive procedures. 19 The hypoesthesia rates in the present study were low with no bothersome cases. Additionally, the maintenance of pain relief rates over the long term were similar to those already published in our CTN general population. 33 We think that patients could benefit more from an initial noninvasive procedure, leaving an open door for those who need further procedures, including MVD and percutaneous techniques. This has to be tailored, of course, to the individual patient and to the baseline assessment.
MVD remains the reference technique for the majority of the surgeons, even in the absence of a prospective randomized comparative trial with a statistically significant number of patients and an adequate follow-up. No definitive answer can be given to the question of the superiority of one technique over the other. Furthermore, significant controversy exists concerning the "ideal" surgical procedure to be applied (initially or as a retreatment) for CTN. MVD is a complex surgical procedure that carries low but significant risks of dreadful complications. That there is usually immediate pain relief and that the procedure directly tackles the supposed cause of the pain by separating the offending vessel (if one exists) from the trigeminal nerve are advantages of MVD. In case of recurrence, however, few neurosurgeons are keen on the idea of going back into a previously operated field, rendering the surgery much more complicated. The present study shows that, in this case, GKS may be extremely helpful with very limited complication rates. However, the significantly lower efficacy rate compared with GKS for CTN without prior MVD has to be kept in mind and explained to the patient, along with the long-term results, which are as good as and comparable to those in our CTN global series.
The majority of authors (among those who have at their disposal the technical and human resources allowing them to do MVD, GKS, or percutaneous techniques) agree that the evidence for the long-term safety and efficacy of GKS is currently sufficient for proposing GKS as a first therapeutic option, following the policy "from less to more invasive." 6, 10, 42, 43 Advantages and disadvantages of each technique must be exposed to the patient according to the data provided by modern peer-reviewed series published over the past 20 years.
CONCLUSION
In our experience, in patients with previous MVD, early pain cessation is lower than in our CTN series, which may be related to a more resistant entity of TN. However, long-term results are good and are comparable to those of our CTN global series, which makes this approach of particular interest in this subgroup of patients.
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